PIK3CA and ovarian cancer: The strategy of utilizing NSAIDs is supported by a study analyzing HNSCC with PIK3CA mutations or amplifications (which may implicate co-occurring AKR1C overexpression as already discussed) where regular NSAID use (≥6 months) markedly prolonged disease-specific survival [48,49] and the Nurses Health cohort study, in which the use of both aspirin- and non-aspirin-based NSAIDs prolonged the survival of ovarian cancer patients using the primary chemotherapeutic agent, cisplatin [50].